Advanced List of Subordinate Units in 2016
Release time:
2020-08-14
2016年度各下属单位先进名单
大冶尖峰
1.优秀班组:质管部分析组
2.优秀管理者:市场营销部 杨振东 环安科 孙世民
3.优秀科技工作者:成品车间 黄焱明
4.安全环保先进工作者:综合管理部 张伟宏
5.优秀员工:
综合管理部 黄再送
财务部 张蓓黎
质管部 刘恒杰
生产部 刘 松
余热发电部 黄文志
技术部 柯善华
制成车间 刘海华 柯建国
成品车间 陈四贵 柯夭容
云南尖峰
1.先进集体:制成车间 成品车间
2.先进班组:
质量管理部分析组 市场营销部开票室 保全部机修班
3.优秀员工
王榀文 石永峰 朱正彬 李学勤 汤忠强 杜先祥
罗宇波 罗忠荣 尚永珍 祝建锋 喻定荣 彭文波
4.优秀科技工作者:董祖国 姚文伟
5.优秀管理工作者:周纪平 朱汝贤
6.优秀营销员:高尚达 邱贤娅
7.优秀共产党员:方旭华 杨顺昌
8.先进工会工作者:陈健康
9.工会积极分子:杨志艳 马 鲲 胡传立
10.安全环保先进工作者:
余 伟 杨林华 罗忠堂 毕忠华 王必成
11.先进党务工作者:谭国坚
12.新秀员工:苏达斌
药业公司
1.先进企业:大药房
2.先进部(室)、车间、门店、班组:
金西厂生产技术科 医药公司采购部
3.优秀管理工作者:
金西厂 王 芬 大药房 陈 珂 天津天然产物 赖建君
4.优秀科技工作者:
开发系统 王庆建 秋滨厂 吴晓明 天津天然产物 刘 莹
5.优秀营销员:
销售公司 方设涛 邱雄飞 医药公司 诸葛红
大药房 王秀玲 天津天然产物 王秀梅
6.优秀员工:
本 部 邵丽莎 李旭金
金西厂 施 展 叶红红 黄义勇
秋滨厂 胡淑珍
销售公司 徐英英
医药公司 李 枫
大药房 方天旭
天津弗兰德 杨雪杰
7.安全环保先进个人:
金西厂 胡浩程 秋滨厂 盛俊勇 大药房 胡一平
8.优秀党员:秋滨厂 庄林芳
9.优秀工会工作者:医药公司 童景春 大药房 陈建云
10.优秀团员:本 部 童艳霞 包菁菁 金西厂 夏碧云
天津尖峰天然产物公司
1.优秀员工:
张富霞 孙万勇 王 英 王 妍 李 月 陈子婵
高 曼 郭晓敏 张月凤 崔 旺 徐 洲 独列玄
许 蕊 宋桂敏 葛文慧 杜忠明
健康科技公司
1.先进集体:保健品事业部销售一部 行政人事部
2.优秀个人:
植物提取事业部生产部 郑红罡
保健品事业部生产部 黄红星
中药饮片事业部生产部 汤新卫 叶 妙
植物提取事业部 冯春嫘
质量部 汪胜峰 曾曲梅
财务部 潘 宇
研发部 刘 佳
采购部 汪 旭
电缆公司
1.优秀员工:朱美仙
2.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31